News

Your employer can finally offer Roth 401(k) matching. So why aren't most workplaces doing it yet?
If you are all in on Roths, it might be a little vexing to you that your employer is not.
Cantech Letter1d
Tesla has price target chopped at Roth
On April 23, Roth lowered its 12-month price target on Tesla (TSLA) to $395 from $450 due to a reduced 2025 revenue forecast ...
Fintel on MSN1d
Roth Capital Initiates Coverage of Fortinet (FTNT) with Neutral Recommendation
Fintel reports that on April 23, 2025, Roth Capital initiated coverage of Fortinet (NasdaqGS:FTNT) with a Neutral ...
Fintel on MSN1d
Roth Capital Initiates Coverage of Check Point Software Technologies (CHKP) with Neutral Recommendation
Fintel reports that on April 23, 2025, Roth Capital initiated coverage of Check Point Software Technologies (NasdaqGS:CHKP) ...
Cantech Letter1d
Meta price target slashed at Roth
In his April 21 first-quarter preview, Rohit Kulkarni, Senior Research Analyst at Roth Capital Partners maintained his “Buy” ...
Fortinet initiated with a Neutral at Roth Capital
Roth Capital initiated coverage of Fortinet (FTNT) with a Neutral rating and $103 price target Fortinet has guided FY25 Product growth to ...
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...
Ainewsbreaks Roth Capital Partners Acted As Lead Manager For Audioeye Inc.'S (NASDAQ: AEYE) $33M Follow-On
AudioEye (NASDAQ: AEYE) , the industry-leading digital accessibility company, previously announced the pricing of the underwritten secondary offering ...
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...
Ur-Energy price target lowered to $1.80 from $2.10 at Roth Capital
Roth Capital lowered the firm’s price target on Ur-Energy (URG) to $1.80 from $2.10 and keeps a Buy rating on the shares. The company provided ...